用血管生成抑制剂贝瓦齐祖马布进行新辅助化疗,用于局部晚期宫癌
Sunhwa Baek1, Ka-Won Noh2, Yue Zhao3
1Department of Obstetrics and Gynecology, University Hospital Cologne and Medical Faculty, Cologne, Germany; sunhwa.baek@uk-koeln.de.
In vivo (Athens, Greece)
|October 30, 2024
概括
将贝瓦齐祖马布添加到新辅助化疗中,改善了宫癌患者的应答率. 虽然没有改善整体存活率,但它显示出优化治疗的潜力,特别是在晚期.
科学领域:
- 妇科瘤学 妇科瘤学
- 医学瘤学 医学瘤学
- 临床癌症研究 临床癌症研究
背景情况:
- 基于的新辅助化疗对复发或转移性宫癌是有效的.
- 贝瓦西祖马布是一种抗血管原体,可以增强化疗的疗效.
- 优化新辅助疗法对于改善宫癌患者的治疗结果至关重要.
研究的目的:
- 评估在宫癌患者中添加贝瓦齐祖马布 (bevacizumab) 加入基新辅助化疗的疗效.
- 评估对应答率,无进展生存率和整体生存率的影响.
- 探索bevacizumab在优化新辅助治疗策略方面的潜力.
主要方法:
- 对40名患有FIGO阶段IB3-IVA宫癌的患者进行了回顾性分析.
- 20名接受新辅助化疗加贝瓦齐祖马布的患者和18名仅接受新辅助化疗的患者之间的比较.
- 评估应答率,无进展生存率和整体生存率.
主要成果:
- 添加贝瓦西祖马布显著改善了反应率 (p=0.046).
- 在没有贝瓦齐祖马布的情况下,无进展的生存率更好,直到FIGO阶段IVA,但在高级阶段 (FIGO IVB) 接受贝瓦齐祖马布时有所改善.
- 总体存活率在各组之间是相似的,尽管在晚期的贝瓦齐祖马布治疗中得到改善. 病态完全缓解是PFS的显著预后因素.
结论:
- 贝瓦西祖马布并没有显著改善整体存活率,但显示出更好的临床反应率的趋势.
- 添加贝瓦齐祖马布证明了优化宫癌新辅助治疗的潜力.
- 需要进一步的研究,以确定在晚期宫癌设置中的最佳使用.
相关概念视频
01:27Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
149
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
149
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K